Search hospitals > Manitoba > WINNIPEG

Health Sciences Centre

Claim this profile
WINNIPEG, Manitoba R3A 1R9
Global Leader in Crohn's Disease
Conducts research for Chronic Kidney Disease
Conducts research for Sepsis
Conducts research for Stroke
Conducts research for Diabetes
141 reported clinical trials
20 medical researchers
Photo of Health Sciences Centre in WINNIPEGPhoto of Health Sciences Centre in WINNIPEGPhoto of Health Sciences Centre in WINNIPEG

Summary

Health Sciences Centre is a medical facility located in WINNIPEG, Manitoba. This center is recognized for care of Crohn's Disease, Chronic Kidney Disease, Sepsis, Stroke, Diabetes and other specialties. Health Sciences Centre is involved with conducting 141 clinical trials across 478 conditions. There are 20 research doctors associated with this hospital, such as Sarvesh Logsetty, MD, Jai Shankar, MD FRCPC, Ryan Zarychanski, MD, and Tanya Sala, MD.

Top PIs

Clinical Trials running at Health Sciences Centre

Stroke
Chronic Kidney Disease
Deep Partial Thickness Burn
Sepsis
Spinal Cord Injury
Postoperative Pain
Depression
Critical Illness
Burns
Human Papillomavirus
Image of trial facility.

Blood Thinners

for Atrial Fibrillation

This trial is testing whether taking blood-thinning pills can prevent strokes and other heart issues in patients who have temporary irregular heartbeats and are at risk of stroke after surgery. These pills are a recent breakthrough in preventing strokes.
Recruiting3 awards Phase 44 criteria
Image of trial facility.

NoNO-42

for Stroke

ACT-42 is a domain of the ACT-GLOBAL platform (NCT06352632). This trial is a Phase 2b, multicenter, prospective, randomized, open label, blinded-endpoint (PROBE) controlled single-dose adaptive trial. A total of up to 600 male and female participants aged ≥ 18 to ≤ 90 years harboring an acute ischemic stroke who are eligible for an intravenous thrombolytic with or without endovascular thrombectomy therapy will be enrolled within 4.5 hours of stroke onset/last known well.
Recruiting1 award Phase 23 criteria
Image of trial facility.

Recombinant Factor VIIa

for Hemorrhagic Stroke

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy. FASTEST Part 2 is an extension of the FASTEST Trial where the subgroups include only those treated within 2 hours with a positive spot sign on a baseline CT angiogram.
Recruiting1 award Phase 32 criteria

Similar Hospitals nearby

Frequently asked questions

What kind of research happens at Health Sciences Centre?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security